WHO Lists Resomelagon Among Six Dengue Drug Candidates for Further Study
The WHO has identified resomelagon, developed by SynAct Pharma, as one of six dengue drug candidates with evidence supporting further clinical development.
The World Health Organization has identified resomelagon as one of six dengue drug candidates that have evidence supporting further clinical development, according to an announcement by SynAct Pharma AB.
The compound, developed by the Swedish biopharmaceutical company, was included in the WHO's set of candidates deemed worthy of continued clinical study. The listing places resomelagon among a small group of drug candidates that the global health body considers to have a sufficient evidence base to justify advancing in the development pipeline.
Dengue remains a significant public health concern in many tropical and subtropical regions, and the identification of promising drug candidates is a step in efforts to expand the range of available treatment options. The WHO's recognition of these six candidates is intended to guide and encourage further clinical research.
SynAct Pharma disclosed the WHO's identification of resomelagon in a brief statement. The company did not provide additional details on the evidence reviewed or on the timelines for any future clinical work.